INTRODUCTION
Once considered an inert constituent of mammalian cell membranes, sphingomyelin (SM, ceramide-phosphocholine) now emerges as the starting point of a complex sphingolipid signalling pathway. Sphingomyelinases (SMases; EC 3.1.4.12), which hydrolyse SM into phosphocholine and ceramide 1 , are key regulatory enzymes of this pathway. In fact, ceramide not only exert multiple biological effects per se, but also elicits the production in cascade of other bioactive sphingolipids, including sphingosine and sphingosine-1-phosphate (S1P) 2, 3 .
According to their optimum pH (alkaline, acid and neutral) SMases isoforms can be divided into three groups, and are further distinguished by their primary structure, localization and cation dependence 4 . Alkaline SMase expression is confined to the intestinal mucosa in many species; in humans, it is also found in the bile and liver 5 . Acid SMases (ASMases) and membrane neutral SMases (NSMases), however, are crucially involved in cardiovascular physiology and pathophysiology 6, 7 . The regulation and roles of sphingolipids and SMases in cell signalling and pathophysiology have been documented in excellent recent reviews by Levade and colleagues 8 , Marchesini and Hannun 9 , Holland and Summers 10 and Smith and Schuchman 11 . In this review, after a brief overview on the central role of ceramide in the complex sphingolipid metabolic and signalling network, we focus on recent advances concerning mechanisms of regulation, and the roles of ASMases and NSMases in the cardiovascular field.
CERAMIDE
Sphingomyelinases ensure ceramide production. The term "ceramide" refers to a family of at least 50 distinct, highly hydrophobic molecules containing a variable length fatty acid carbons) linked to sphingosine or a related long chain base. Ceramide metabolism generates a cascade of bioactive lipids, all of which carry a specific signalling capacity. This sphingolipid signalling network is found in the different cardiovascular system cell types and is critically
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4 involved in cell proliferation, cell death and cardiac myocyte (CM) and vascular smooth muscle cell (VSMC) contraction 8 .
Most enzymes involved in sphingolipid metabolism show specific subcellular localisation.
The lysosomal ASMase, L-ASMase, localises primarily in the endolysosomal compartment, but under certain conditions it can relocate to the outer leaflet of the plasma membrane 4, 9 . NSMase has been identified in the endoplasmic reticulum and the Golgi apparatus 4, 12 , but would also localise in the inner leaflet of the plasma membranes 2, 13, 14 . Ceramide levels may therefore be regulated by distinct mechanisms and in distinct compartments. Ceramide is converted by ceramidase into sphingosine, which in turn is phosphorylated by sphingosine kinase into S1P.
These lipids exert opposite biological effects: ceramide and sphingosine are primarily antiproliferative and pro-apoptotic, whereas S1P promotes cell growth and counteracts apoptotic stimuli. As a result, the ratio between ceramide plus sphingosine and the S1P level (also referred to as the ceramide/S1P rheostat) is the true determinant of a cell's fate, rather than the individual ceramide, sphingosine or S1P levels 15 .
In addition to its production via sphingomyelin hydrolysis, ceramide can be created by a "de novo" pathway, the first and rate-limiting step of which is the condensation of palmitoyl coA with serine by serine palmitoyltransferase 3, 16 . Using pharmacologic and genetic methods targeting the serine palmitoyltransferase, Park and colleagues have shown that the de novo ceramide pathway is involved not only in the pathogenesis of lipotoxic cardiomyopathy 17 but also in the formation of atherogenic plaques 18 . These authors further showed that myriocin, a serine palmitoyltransferase inhibitor, lowered plasma sphingolipids and atherogenic plasma lipids, leading to the regression of pre-existing atherosclerotic lesions and the formation of a stable plaque phenotype. This implies that the regulation of sphingolipid biosynthesis may have clinical applications in the treatment of advanced atherosclerosis 18 .
SMASE ASSAYS
SMase activity is generally not difficult to measure, although it requires a certain amount of biological material. It can be assayed in vivo through labelling of cells with a radioactive SM precursor, or in vitro using either radiolabelled SM or chromogenic, coloured or fluorescent injury, but it does not lessen their significance. ASMase activity occurs in all cardiac tissue examined in the rat, the mouse and in humans 28, 34 . It fulfils an essential housekeeping function in lysosomes, as shown by the multi organ abnormalities in NPD, which results from lysosomal sphingomyelin accumulation due to ASMase deficiency 23, 35 . ASMase activity also contributes to cellular signalling in response to external stress stimuli including ischaemia/reperfusion and stimulation of diverse receptors in the TNF receptor superfamily.
Prolonged myocardial ischaemia inevitably results in cell death, and the duration of ischaemia is a primary determinant of infarct size. Reoxygenation through reperfusion reduces ischaemic damage, but also triggers additional cell death 36 . Preconditioning, which consists of applying transient episodes of ischaemia/reperfusion before the sustained ischaemic event,
protects the heart from ischaemia/reperfusion injury 37 by limiting apoptosis, both in vitro 38 and in vivo 39 . Post-conditioning has recently emerged as a more relevant clinical strategy; it consists of applying transient episodes of ischaemia/reperfusion after the sustained ischaemic event,
instead of before 40, 41 . Pre-and post-conditioning cardioprotective strategies may rely on a similar signalling pathway in the reperfused heart 42 .
Several studies suggest a causal relationship between the increase in ceramide content and CM death in the post-ischaemic reperfused rat heart [43] [44] [45] . Argaud and colleagues 46 have
shown that benefits of preconditioning are related to reduced cardiac ceramide content. The
ASMase inhibitor, tricyclodecan 9 y-xanthate (D609), administered before the ischaemic period, reproduces preconditioning protection, proving the contribution of ASMase activity in the ischaemia-induced cell death 46 . However, Lecour and colleagues 47 report that preconditioning with TNF-alpha, that is likely to activate ASMase and/ or NSMase 9 , also exerts an ischaemic preconditioning-like protection. TNF-alpha protection is reproduced by the cell-permeable C2-ceramide. The discrepancy between these two reports probably illustrates the multiple responses that ceramide may mediate depending on its subcellular location, which determines its proximal targets and downstream metabolism 3 . It may be that ASMase activation triggered by the ischaemic preconditioning provides ceramide integral to a cell death pathway, whereas TNF-alpha and cell permeable C2-ceramide release ceramide for the ceramidase/ sphingosine kinase metabolism cascade. In fact, the ceramidase inhibitor N-oleoylethanolamine (NOE)
hinders the preconditioning-like protection provided by TNF-alpha or C2-ceramide, but does not
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hinder the protection induced by ischaemic preconditioning 47 .
Using the tricyclic antidepressant inhibitor desipramine (a potent ASMase inhibitor), Das and colleagues 48, 49 document the two-edged role of ceramide, mediating protection in ischaemic preconditioning but promoting apoptosis after the ischaemia/reperfusion event. Thus, ASMasemediated accumulation of ceramide in the ischaemic heart is causally related with apoptosis and cardiac dysfunction. In contrast, ischaemic preconditioning leads to a limited accumulation of ceramide in the ischaemic/reperfused heart, along with an increase in S1P content 48 . The connection is seen between ceramide generated in lipid rafts during ischaemia/reperfusion, and the increased association of endothelial nitric oxide synthase (eNOS) with caveolin-1, which makes endothelial NO unavailable to the ischaemic heart 49 . It is worth noting that deletion of the sphingosine kinase 1 gene abolishes the cardioprotection produced by either ischaemic preconditioning or ischaemic postconditioning 50, 51 .
The lysosomal (L) and secreted (S) isoforms of ASMase
In the late 90's, Tabas 8 from the lysosomal trafficking pathway and into the Golgi secretory pathway 54, 55 .
L-ASMase and vascular tone
In human lymphocytes, Grassmé and colleagues 56 were the first to show that diverse receptors, belonging to the TNF receptor superfamily and mediating apoptosis, triggered LASMase translocation from lysosomes to the extracellular surface of the cell membrane. The 
S-ASMase in atherosclerosis
Both proliferation and death of VSMCs contribute to the progression of the atherosclerotic lesions. Levade and colleagues 62 were the first to reveal the possible involvement of the sphingomyelin/ ceramide pathway in atherogenesis, through a mitogenic effect on VSMCs. ECs, which cover the atherosclerotic lesions, secrete S-ASMase. Enzyme secretion is enhanced by atherogenic pro-inflammatory cytokines 55 . Secreted-ASMase hydrolyses sphingomyelin to ceramide on the surface of atherogenic lipoprotein particles, even at neutral pH 63 . The resulting increase in lipoprotein ceramide promotes fusion and subendothelial aggregation of the lipoprotein particles, increasing their affinity for arterial wall proteoglycans and leading to foam cell formation 64 . Studies in patients and experimental models confirm the presence of SASMase in atherosclerotic lesions 65 , and show that the latter are significantly decreased upon pharmacological inhibition of sphingomyelin synthesis 66 68 showed that ASMase deficiency reduces both lesion development and arterial trapping of atherogenic lipoproteins.
S-ASMase in heart failure
In addition to neuro-hormonal activation, inflammation and oxidative stress are key components in chronic heart failure (HF) progression [69] [70] [71] and severity [72] [73] [74] . The ability of proinflammatory cytokines to trigger S-ASMase secretion from ECs 55, 75 , combined with the stimulatory effect of reactive oxygen species (ROS) on enzyme activity [76] [77] [78] are possible mechanisms explaining the increase in plasma S-ASMase activity in patients with HF 79 . In their pilot study, Anker and colleagues discovered that this activity is increased by 90% in patients with HF, compared with controls, and was a significant predictor of impaired survival 79 . Plasma S-ASMase activity was positively related to the disease severity (assessed by the New York Heart Association functional class and peak oxygen uptake), and main clinical markers (including creatinine, uric acid, plasma TNF-alpha and sTNFR1). Impaired peripheral blood flow and vasodilator capacity is also associated with S-ASMase activation 79 . This is relevant to the previously reported increase in plasma levels of TNF-alpha in heart failure patients with impaired peripheral blood flow 80 , and the finding by Zhang et al 81 that desipramine neutralises the inhibitory effect of TNF-alpha on endothelium-dependent vasorelaxation.
MULTIPLE NSMASES
Clarke and Hannun recently reviewed overall NSMase properties and physiological roles 32, 82 . NSMase hydrolyses a SM pool located in the inner leaflet of the plasma membrane 13, 14 . In the different cardiovascular system cell types, several external stimuli trigger 
NSMase signalling pathways
In isolated CM, NSMase mediates apoptosis elicited by TNF-alpha 83, 84 or IL-1beta 85 .
TNF-alpha activates the NSMase3 isoform through its recruitment to TNFR1 by the FAN adapter protein 86, 87 . Inhibition by the tripeptide glutathione (L-γ-glutamyl-cysteinyl-glycine) is a common feature of NSMase isoforms 1 and 3 30, 88 . In fact, we have shown that cellular glutathione determines NSMase responsiveness to TNF-alpha 89, 90 , and that the enzyme's activation in failing rat and human hearts is related to a deficiency in glutathione 91, 92 .
In cultured VSMC, apolipoprotein C-1 (apoC-1)-enriched high-density lipoproteins (HDLs)
stimulate NSMase, triggering an apoptotic response via the release of cytochrome c from mitochondria and caspase-3 activation 93 . Oxidised low-density lipoproteins (oxLDLs) and TNFalpha also stimulate NSMase in VSMCs 94, 95 . However, these stimuli do not trigger apoptosis, but instead contribute to VSMC proliferation resulting from the metabolism of ceramide into S1P, and downstream activation of ERK1/2 MAPKinases 94,95 . In cultured VSMC and using the small interfering RNA strategy (siRNA), Auge et al. demonstrated both, the specific involvement of the NSMase2 isoform in the mitogenic effect of ROS 96 and oxLDL 97 , and the process of NSMase2 activation that relies on a proteolytic cascade involving furin/ MT1-MPP/MMP-2 proteases 96, 97 . This MMP/ NSMase2 pathway also drives the mitogenic effect of TNF-alpha on VSMC 95 .
In cultured bovine aortic EC, the cellular response to mechanical stimulation is inhibited by the NSMase inhibitor scyphostatin, and is reproduced by addtion of exogenous bacterial NSMase or ceramide 14 . As Schnitzer and colleagues discovered, using microvascular lung EC, the mechanoactivation signalling pathway relies on ceramide generation in caveolae, and on eNOS phosphorylation and activation 14, 98, 99 . This is in agreement with a study in isolated arteries showing that exogenous bacterial NSMase triggers vasorelaxation via eNOS phosphorylation and activation, independently of raised intracellular Ca 2+ level 100 . In contrast,
NSMase activation in ageing rat arteries is related to ceramide-activated protein phosphatase 2A activity and subsequent decrease in eNOS phosphorylation and activation, leading to a loss
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of vasomotor function 101 . Recently, Smith et al. 102 (commented in 103 ) further showed that lipoic acid supplementation of isolated aortic rings reversed age-related loss of endothelial glutathione, leading to reduced NSMase activation and ceramide level in the endothelium and improved endothelial NO-dependent vasomotor function.
NSMase in ischaemia/reperfusion
Early NSMase activation in isolated CM in response to hypoxia/reoxygenation 104 is consistent with the reported deficiency in cardiac glutathione (its cellular inhibitor) following ischaemia/reperfusion in isolated hearts or in vivo [105] [106] [107] [108] . In isolated CM, NSMase/sphingosine pathway determines the apoptotic response to hypoxia/reoxygenation 104, 109 or TNF-alpha 83, 87 that involves the impairment of the mitochondrial function 110 and/or the activation of caspases 92, 111 . In addition, the NSMase/sphingosine pathway promotes the negative effect on CM contraction triggered by TNF-alpha 84, 112 or IL1-beta 85 . Taken together, these in vitro findings indicate the deleterious consequences of NSMase/sphingosine pathway activation on CM survival and functioning, and predict a critical role for NSMase in the development of cardiac failure.
NSMase in heart failure
Oxidative stress and inflammation are major interrelated contributors to the development of HF. Glutathione contributes to many metabolic cell functions, in particular cell defence against oxidative stress, and is essential to cell survival. In its reduced form (GSH), glutathione serves as a cofactor to glutathione peroxidase to reduce intracellular ROS, being oxidized to the disulfide-linked dimer (GSSG). In situations involving prolonged oxidative stimuli, GSSG cannot be recycled, and is pumped out of the cell such that the cellular glutathione content decreases if glutathione is not resynthesized through other pathways. In the failing heart, prolonged oxidative stress creates cardiac glutathione deficiency; this deficiency, together with TNF-alpha upregulation, causes NSMase activation 91, 92 . However, in animal models, glutathione repletion on the impairment of S1P-induced cardiac myofibroblast activation 113 .
NSMase in atherosclerosis
Apoptosis of VSMCs is a critical event in the rupture of the atherosclerotic plaque, leading to thrombosis, myocardial infarction, and possible death. In vitro studies highlight the ability of apoC-1 enriched HDLs to induce VSMC death via NSMase activation 93 . In patients, the apoC-1 content of lipoprotein remnants appears as an early marker of coronary artery disease risk 114 .
Using a Watanabe hyperlipidaemic rabbit model of plaque rupture and employing novel noninvasive advanced high-resolution MRI techniques, Steen and colleagues 115 , further established the colocalisation of apoC-1, ceramide, caspase-1 and 3 in regions of plaque rupture, thus pointing to an in vivo relevance of the in vitro findings.
Via NSMase activation, oxLDLs induce cultured VSMC proliferation 94, 97 , which in situ contributes to the formation and progression of atherosclerotic lesions. Ox-LDLs are present in both animal and human atherosclerotic lesions and trigger the progression of atherosclerosis and plaque rupture 116 .
CONCLUSION: THERAPEUTIC PERSPECTIVES
It is now clear that stress-induced activation of ASMases and NSMases, may contribute in different ways to the development of cardiac and vascular dysfunction (Table 1) .
ASMase deficiency in NPD leads to lipid abnormalities that may be associated with early atherosclerotic heart disease 117 . Nevertheless, S-ASMase activation in atherosclerotic lesions contributes to the progression of the lesion 64, 68 . These results imply therefore that therapy for 121 .
NSMase activation is associated with heart failure progression and endothelial dysfunction. The most studied specific inhibitors of NSMase include scyphostatin 122 and GW4869 123 which inhibit vascular EC NSMase activity when added either to the cell medium or to the isolated vessel perfusate 14, 101 . However, in vivo, the effectiveness of scyphostatin has only been documented in a rat model of paw oedema 122 .
Another new nonspecific ASMase and NSMase inhibitor (SMA-7, a difluoromethylene analogue of sphingomyelin) reduces colitis in mice when given orally 124 . Such a lack of specificity may be advantageous in pathological situations with concomitant activation of ASMase and NSMase. In contrast, glutathione specifically inhibits NSMase, and cellular glutathione content is a major determinant of cellular NSMase activity 88, 125 . Ageing and most of the chronic inflammatory diseases are featured by systemic and/or tissue glutathione deficiency.
Several studies in animal models and patients suggest that oral or intra-peritoneal administration of NAC or lipoic acid (which are both antioxidant molecules, but are above all precursors of glutathione) restored tissue glutathione. In HF, as in age-related decline in vasomotion, the benefits of NAC or lipoic acid treatment are related to NSMase inhibition 92,102 .
In conclusion, SMases are potential targets for drug development in the treatment of atherosclerosis, heart failure and age-related cardiovascular diseases. In particular, ASMase inhibitors could be tools against post-ischaemia reperfusion injury, and in the treatment of atherosclerosis, bearing in mind that S-ASMase might be a preferable target than L- 
